Ermutcin capsules contain erdosteine and help clear mucus in acute and chronic respiratory diseases.
Composition:
Each hard capsule contains:
Active ingredient: Erdosteine 300 mg.
Excipients: Microcrystalline cellulose, povidone K30, magnesium stearate.
Capsule shell:
Body: Gelatin, titanium dioxide (E171), yellow iron oxide (E172).
Cap: Gelatin, titanium dioxide (E171), yellow iron oxide (E172), indigo carmine (E132).
Indications:
Acute inflammatory diseases of the respiratory tract (rhinitis, sinusitis, laryngopharyngitis, acute bronchitis).
Exacerbations of chronic respiratory diseases (chronic bronchitis, chronic obstructive pulmonary disease, hypersecretory asthma, bronchiectasis, and chronic smoker's bronchitis, including seasonal exacerbations).
Combination therapy with antibiotics for exacerbations of bronchitis of bacterial origin.
Prevention of pneumonia and partial atelectasis following surgery.
Contraindications:
Confirmed hypersensitivity to the ingredients of the medicine or substances containing free SH groups.
Hepatic dysfunction (e.g., elevated alkaline phosphatase or transaminase levels).
Renal failure (creatinine clearance below 25 mL/min).
Homocystinuria (the medicine is a source of homocysteine; therefore, it may disrupt amino acid metabolism in patients following a diet low in free methionine).
Active peptic ulcer.
Method of Administration and Dosage:
Adults: 1 capsule (300 mg) 2–3 times daily.
Ermutcin capsules are intended for the treatment of adults. The medicine is taken orally.
The course of treatment lasts 7–10 days, which is sufficient to achieve the full therapeutic effect. In chronic diseases, the medicine may be used for a longer period when medically indicated.
Possible Side Effects:
Rarely: heartburn, nausea, diarrhea, skin redness, and urticaria.
If any side effect occurs, including one not listed in these instructions, consult your doctor or pharmacist.
Interactions with Other Medicines:
No side effects have been observed when Ermutcin is used concomitantly with medicines commonly used for chronic obstructive pulmonary disease and respiratory conditions, such as theophylline, bronchodilators, erythromycin, amoxicillin, or sulfamethoxazole.
Erdosteine enhances the effects of certain antibiotics, such as amoxicillin and clarithromycin, which may be used for therapeutic purposes.
A synergistic interaction with budesonide and salbutamol has been confirmed.
Special Warnings and Precautions:
If typical symptoms of hypersensitivity occur, treatment should be discontinued immediately.
Concomitant use with other antitussive medicines is not rational, as it may lead to the accumulation of liquid secretions in the bronchi and increase the risk of superinfection or bronchospasm.
Use During Pregnancy and Breastfeeding:
Experience with the use of this medicine during pregnancy and breastfeeding is limited. Therefore, it should be used during these periods, especially in the first trimester of pregnancy, only when absolutely necessary.
Symptoms of Overdose and Treatment:
No cases of overdose have been reported. However, symptomatic treatment is recommended in the event of an overdose.
Presentation:
10 hard capsules in a PVC-PVDC and aluminum foil blister pack. Two blisters, together with the instructions, are supplied in a cardboard box.
Storage Conditions:
Store at a temperature not exceeding 25°C, out of the reach of children.
Shelf Life: 5 years.
Do not use after the expiry date indicated on the package.
Dosage Form: Hard capsule.
Description:
Hard gelatin capsules with a yellow body and a green cap. The capsule contents are white or almost white powder.
Dispensing Conditions: As directed by the pharmacist.
